Orbimed Advisors LLC acquired a new position in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 394,270 shares of the company’s stock, valued at approximately $7,487,000. Orbimed Advisors LLC owned 1.24% of Deciphera Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DCPH. Emerald Advisers Inc. PA acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $6,661,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $5,548,000. Kornitzer Capital Management Inc. KS acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $2,172,000. SG Americas Securities LLC acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $143,000. Finally, Sphera Funds Management LTD. acquired a new stake in Deciphera Pharmaceuticals in the third quarter valued at $1,424,000. 43.94% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) opened at $18.21 on Monday. Deciphera Pharmaceuticals Inc has a twelve month low of $16.11 and a twelve month high of $24.50.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($5.30). analysts forecast that Deciphera Pharmaceuticals Inc will post -2.91 EPS for the current fiscal year.

In related news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

DCPH has been the topic of several research reports. J P Morgan Chase & Co initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $30.00 target price on the stock. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “outperform” rating and a $38.00 target price on the stock. Instinet initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Nomura initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 target price on the stock. Five analysts have rated the stock with a buy rating, Deciphera Pharmaceuticals currently has an average rating of “Buy” and an average target price of $43.40.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/orbimed-advisors-llc-takes-position-in-deciphera-pharmaceuticals-inc-dcph/1756670.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.